Current and historical daily PE Ratio for Genmab A/S (
STU:GE91
) from 2019 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Genmab A/S stock (STU:GE91) PE ratio as of May 28 2024 is 23.27.
More Details
Genmab A/S (STU:GE91) PE Ratio (TTM) Chart
Genmab A/S (STU:GE91) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 1224
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Genmab A/S PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-28 | 23.2 | 2024-03-21 | 30.8 |
| 2024-05-27 | 23.2 | 2024-03-20 | 30.8 |
| 2024-05-24 | 24.3 | 2024-03-19 | 30.4 |
| 2024-05-23 | 24.7 | 2024-03-18 | 31.0 |
| 2024-05-22 | 24.8 | 2024-03-15 | 31.5 |
| 2024-05-21 | 24.1 | 2024-03-14 | 31.9 |
| 2024-05-20 | 24.8 | 2024-03-13 | 32.2 |
| 2024-05-17 | 24.5 | 2024-03-12 | 32.2 |
| 2024-05-16 | 24.5 | 2024-03-11 | 32.4 |
| 2024-05-15 | 24.5 | 2024-03-08 | 30.4 |
| 2024-05-14 | 24.3 | 2024-03-07 | 30.4 |
| 2024-05-13 | 23.8 | 2024-03-06 | 30.1 |
| 2024-05-10 | 23.9 | 2024-03-05 | 29.9 |
| 2024-05-09 | 23.9 | 2024-03-04 | 29.9 |
| 2024-05-08 | 24.3 | 2024-03-01 | 29.9 |
| 2024-05-07 | 23.9 | 2024-02-29 | 29.2 |
| 2024-05-06 | 24.3 | 2024-02-28 | 29.7 |
| 2024-05-03 | 24.7 | 2024-02-27 | 30.1 |
| 2024-05-02 | 23.4 | 2024-02-26 | 30.6 |
| 2024-04-30 | 23.4 | 2024-02-23 | 30.4 |
| 2024-04-29 | 23.4 | 2024-02-22 | 30.1 |
| 2024-04-26 | 23.6 | 2024-02-21 | 29.9 |
| 2024-04-25 | 23.2 | 2024-02-20 | 30.1 |
| 2024-04-24 | 23.9 | 2024-02-19 | 30.1 |
| 2024-04-23 | 24.5 | 2024-02-16 | 29.9 |
| 2024-04-22 | 24.1 | 2024-02-15 | 28.8 |
| 2024-04-19 | 23.8 | 2024-02-14 | 27.6 |
| 2024-04-18 | 23.9 | 2024-02-13 | 28.8 |
| 2024-04-17 | 24.8 | 2024-02-12 | 29.0 |
| 2024-04-16 | 24.8 | 2024-02-09 | 29.0 |
| 2024-04-15 | 24.7 | 2024-02-08 | 29.2 |
| 2024-04-12 | 25.2 | 2024-02-07 | 29.4 |
| 2024-04-11 | 24.8 | 2024-02-06 | 29.4 |
| 2024-04-10 | 24.3 | 2024-02-05 | 28.8 |
| 2024-04-09 | 24.7 | 2024-02-02 | 28.8 |
| 2024-04-08 | 24.7 | 2024-02-01 | 29.0 |
| 2024-04-05 | 24.7 | 2024-01-31 | 29.0 |
| 2024-04-04 | 25.0 | 2024-01-30 | 29.7 |
| 2024-04-03 | 24.3 | 2024-01-29 | 28.8 |
| 2024-04-02 | 25.2 | 2024-01-26 | 29.2 |
| 2024-03-28 | 25.0 | 2024-01-25 | 28.8 |
| 2024-03-27 | 31.7 | 2024-01-24 | 28.8 |
| 2024-03-26 | 31.9 | 2024-01-23 | 29.2 |
| 2024-03-25 | 31.3 | 2024-01-22 | 29.4 |
| 2024-03-22 | 31.0 | 2024-01-19 | 29.7 |
Genmab A/S (STU:GE91) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Genmab A/S
ISIN : US3723032062
Share Class Description:
STU:GE91: ADRCompare
Compare
Traded in other countries / regions
GMAB.USAGMAB.Denmark0MGB.UKGMAB.MexicoGE91.GermanyGMAB.Austria IPO Date
2019-07-18Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers